Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesModerna Inc

Moderna Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
271.53 USD 17.34 ( 6.82%)
Last update at 2026-11-09T15:39:00Z
VOLUME
3837534
Market Cap
57398.15M

Momentum Score

…

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
253.33
Low
274.88
High
52 Week Price Range
22.28
Low
176.66
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Moderna develops medicines using mRNA technology, commercializing vaccines and advancing therapeutics in infectious disease, oncology and rare conditions. Long-term growth may be driven by platform expansion, new respiratory and seasonal vaccine launches, and clinical progress in personalized oncology, which could support recurring revenue and pipeline value. Manufacturing scale and regulatory experience appear positioned to accelerate development and commercialization across multiple indications. Material risks include revenue concentration from COVID-19 products, clinical trial and regulatory setbacks, intense competition in vaccines and therapeutics, and manufacturing, pricing and demand variability.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
254.19
Dividend Yield
-
Revenue TTM
2228.00M
Revenue Per Share
5.66
Gross Profit TTM
-1471.00M
Debt / Equity
0.22
ROE
-39.00%
Net Debt
-679.00M
ROCE
-26.74%
Diluted EPS TTM
-7.82

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2768.00M -3607.00M -3942.00M 9575.00M 13285.00M
Net income -2822.00M -3561.00M -4714.00M 8362.00M 12202.00M
Selling general administrative 1018.00M 1028.00M 1345.00M 1132.00M 567.00M
Selling and marketing expenses - 146.00M 204.00M - -
Gross profit 1076.00M 1735.00M 2155.00M 13847.00M 15119.00M
Reconciled depreciation 215.00M 189.00M 499.00M 348.00M 232.00M
Ebit -2768.00M -3583.00M -3904.00M 9420.00M 13064.00M
Ebitda -2553.00M -3394.00M -3283.00M 9768.00M 13296.00M
Depreciation and amortization 215.00M 189.00M 621.00M 348.00M 232.00M
Non operating income net other - - - 155.00M -11.00M
Operating income -3074.00M -3945.00M -4239.00M 9420.00M 13296.00M
Other operating expenses 5018.00M 7144.00M 11087.00M 9843.00M 4440.00M
Interest expense 10.00M 24.00M 38.00M 29.00M 18.00M
Tax provision 54.00M -46.00M 1109.00M 1213.00M 1083.00M
Interest income 314.00M 425.00M 405.00M 200.00M 18.00M
Net interest income 304.00M 401.00M 363.00M 200.00M 18.00M
Income tax expense 54.00M -46.00M 772.00M 1213.00M 1083.00M
Total revenue 1944.00M 3199.00M 6848.00M 19263.00M 17736.00M
Total operating expenses 4150.00M 5680.00M 6394.00M 4427.00M 1823.00M
Cost of revenue 868.00M 1464.00M 4693.00M 5416.00M 2617.00M
Total other income expense net 306.00M 338.00M 297.00M 155.00M -11.00M
Net income from continuing ops -2822.00M -3561.00M -3466.00M 8362.00M 12202.00M
Net income applicable to common shares - - - 8362.00M 12202.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 12338.00M 14142.00M 18426.00M 25858.00M 24669.00M
Intangible assets 45.00M 40.00M 44.00M - -
Other current assets 308.00M 365.00M 88.00M 1195.00M 55.00M
Total liab 3688.00M 3241.00M 4572.00M 6735.00M 10524.00M
Total stockholder equity 8650.00M 10901.00M 13854.00M 19123.00M 14145.00M
Other current liab 1571.00M 1608.00M 1902.00M 2202.00M 2362.00M
Common stock - - - - -857.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings 7223.00M 10045.00M 13606.00M 18320.00M 9958.00M
Other liab - - - 808.00M 691.00M
Good will 52.00M 52.00M 52.00M - -
Other assets - - - 1928.00M 7383.00M
Cash 2595.00M 1927.00M 2907.00M 3205.00M 6848.00M
Total current liabilities 1987.00M 2206.00M 3015.00M 4923.00M 9128.00M
Current deferred revenue 99.00M 153.00M 568.00M 2038.00M 6253.00M
Net debt -679.00M -1180.00M -1664.00M -2005.00M -5932.00M
Short term debt - 37.00M 25.00M 196.00M 211.00M
Short long term debt total 1916.00M 747.00M 1243.00M 1200.00M 916.00M
Other stockholder equity 1382.00M 866.00M 371.00M 1173.00M 4211.00M
Property plant equipment - - - 2139.00M 1383.00M
Total current assets 6544.00M 8099.00M 10325.00M 13431.00M 17570.00M
Long term investments 2342.00M 2508.00M 4743.00M 8318.00M 6843.00M
Net tangible assets - - - 19123.00M 14145.00M
Short term investments 3204.00M 5098.00M 5697.00M 6697.00M 3879.00M
Net receivables 284.00M 592.00M 1081.00M 1385.00M 3296.00M
Long term debt 590.00M - - - -
Inventory 153.00M 117.00M 202.00M 949.00M 1441.00M
Accounts payable 317.00M 405.00M 520.00M 487.00M 302.00M
Accumulated other comprehensive income 45.00M -10.00M -123.00M -370.00M -24.00M
Retained earnings total equity - - - 18320.00M 9958.00M
Non currrent assets other 421.00M 407.00M 523.00M 988.00M 46.00M
Non current assets total 5794.00M 6043.00M 8101.00M 12427.00M 7099.00M
Capital lease obligations 715.00M 747.00M 1243.00M 1004.00M 916.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 2148.00M 1949.00M 3696.00M -5176.00M -8239.00M
Change to liabilities - - - 112.00M 2192.00M
Total cashflows from investing activities 1946.00M 1949.00M 4206.00M -5176.00M -8523.00M
Net borrowings 560.00M -10.00M -270.00M -184.00M -140.00M
Total cash from financing activities 593.00M 56.00M -1377.00M -3448.00M -873.00M
Change to operating activities - - - -992.00M 582.00M
Net income -2822.00M -3561.00M -4714.00M 8362.00M 12202.00M
Change in cash 668.00M -999.00M -289.00M -3643.00M 4224.00M
Begin period cash flow 1929.00M 2928.00M 3217.00M 6860.00M 2636.00M
End period cash flow 2597.00M 1929.00M 2928.00M 3217.00M 6860.00M
Total cash from operating activities -1873.00M -3004.00M -3118.00M 4981.00M 13620.00M
Issuance of capital stock 35.00M 66.00M 46.00M 0.00M 0.00M
Depreciation 215.00M 189.00M 621.00M 348.00M 232.00M
Other cashflows from investing activities -10.00M - -23.00M -40.00M -30.00M
Dividends paid - - 270.00M - -124.00M
Change to inventory -34.00M 83.00M 747.00M 492.00M -1394.00M
Change to account receivables 156.00M 534.00M 493.00M 1790.00M -1784.00M
Sale purchase of stock - 0.00M -1153.00M -3329.00M -857.00M
Other cashflows from financing activities 19.00M 56.00M 4206.00M -184.00M 124.00M
Change to netincome - - - -305.00M -176.00M
Capital expenditures 192.00M 1051.00M 707.00M 400.00M 284.00M
Change receivables - - - 1790.00M -1784.00M
Cash flows other operating - - - -5849.00M 2294.00M
Cash and cash equivalents changes - - - -3643.00M 4224.00M
Change in working capital 254.00M -78.00M -139.00M -3455.00M 990.00M
Stock based compensation 483.00M 429.00M 305.00M 226.00M 142.00M
Other non cash items -3.00M 17.00M -19.00M 59.00M 372.00M
Free cash flow -2065.00M -4055.00M -3825.00M 4581.00M 13336.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MRNA
Moderna Inc		 17.34
6.82%		 271.53 - 23.04 25.76 8.66 24.76 4.64
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Moderna Inc

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

325 Binney Street, Cambridge, MA, United States, 02142

617 714 6500

https://www.modernatx.com

4700

Name Title Year Born
Dr. Noubar B. Afeyan Ph.D. Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board 1963
Mr. Stephane Bancel CEO & Director 1973
Dr. Stephen Hoge M.D. Pres 1976
Ms. Shannon Thyme Klinger Chief Legal Officer & Corp. Sec. 1971
Mr. Juan Andres Pres of Strategic Partnerships & Enterprise Expansion 1965
Mr. James M. Mock Chief Financial Officer 1977
Dr. Jerh Collins Ph.D. Chief Technical Operations & Quality Officer NA
Dr. John V. W. Reynders Ph.D. Chief Information Officer NA
Dr. Melissa J. Moore Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board NA
Ms. Lavina Talukdar CFA Sr. VP & Head of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.63%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.18%

  • Financial Services

    +1.33%

  • Healthcare

    +1.49%

  • Industrials

    +2.99%

  • Real Estate

    +0.41%

  • Technology

    +1.45%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…